Lin, J., Zhou, Q., Yan, H., Chu, Q., Wu, G., Liu, A., Cui, J., Liu, Y., Xu, H., Du, Y., Yang, Y., Tu, H., Wu, Y., Liu, S. M. (2026). Implementing flexible and adapted follow-up strategies in a patient-centric, phase II trial of first-line lorlatinib for advanced ALK-positive non–small cell lung cancer (CTONG2203).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e13545